List view / Grid view
17 November 2016 | By Leif Poulsen, Global technology Partner, NNE Pharmaplan
European Pharmaceutical Review brought you all the latest research and development live from the conference. Now read NNE Pharmaplan's Leif Poulsen's round up of the event…
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
D is for Dementia - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research on Dementia...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
We caught up with Bonesupport's CEO Richard Davies to find out how they're using artificial bone grafts to help sufferers of chronic osteomyelitis...
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for Cancer Drugs Fund - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest on the Cancer Drugs Fund
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
B is for Biosimilar - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biosimilars.
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Antibiotics - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of antibiotics.
14 November 2016 | By Norma McGough, Director of Policy, Research & Campaigns, Coeliac UK
Coeliac UK’s Director of Policy, Research & Campaigns, Norma McGough, welcomes NICE’s new quality standards on coeliac disease, which she believes will bring clarity and improvement to diagnosis screening and better access to long term treatment…
7 November 2016 | By Jurgi Camblong, CEO and co-founder of Sophia Genetics
Sophia Genetics' CEO Jurgi Camblong says genomic data can now diagnose and tailor individual treatments but how do we democratise Data-Driven Medicine?
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review caught up with HDA's Executive Director Martin Sawer to discuss the letter and how Brexit will affect the industry...
20 October 2016 | By European Pharmaceutical Review
In this issue: Biosimilars, Informatics, Ingredients, PAT, HPLC, Microbiology, Product Showcase, Regulation, and much more...
This product showcase features articles from Charles River, Eppendorf Inc. and Eurofins Lancaster Laboratories...
In this Ingredients In-Depth Focus: Excipient quality and supplier interchangeability; Interpreting ICH’s evolving residual solvents guideline; Q&A with Meggle...
In this HPLC In-Depth Focus: Resolving natural compound complexity with multidimensional chromatography; The advantages of temperature elevations in HPLC...
In the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides,…
Intellectual Property (IP) is the lifeblood of the pharmaceutical industry. Without it, there would not be much of a business. Growing research and development globalisation, externalisation, the expansion of electronic data management systems and the lack of consistent global IP enforcement is increasing the capacity of external and internal parties…
